Ponatinib

• CAT Number: A001082
• CAS Number: 943319-70-8
• Molecular Formula: C₂₉H₂₇F₃N₆O
• Molecular Weight: 532.56
• Purity: ≥95%
• Target: Bcr-Abl
• Solubility: Soluble in DMSO > 10 mM
• Storage: 3 years -20C powder
• IUPAC Name: 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
• InChI: InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
• InChIKey: PHXJVRSECIGDHY-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5

Ponatinib（Cat No.:A001082）is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is particularly effective in patients with the T315I mutation, resistant to other treatments. Ponatinib works by inhibiting BCR-ABL, a protein driving cancer cell proliferation. Its potent action across multiple kinase targets makes it a vital option for managing resistant or advanced stages of these leukemias. Careful monitoring is essential due to potential cardiovascular side effects, but its targeted efficacy offers hope for patients with limited options.